@article{TCR34463,
author = {Zhi-Hong Xu and Heng Zhang and Deng-Hui Wei and Li-Li Xie and Chun-Sen Xu},
title = {Cyclin-dependent kinase 4/6 inhibitor in combination with endocrine therapy versus endocrine therapy only for advanced breast cancer: a systematic review and meta-analysis},
journal = {Translational Cancer Research},
volume = {9},
number = {2},
year = {2019},
keywords = {},
abstract = {Background: The resistance to endocrine therapy poses a significant challenge to the management of advanced breast cancer with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (Her-2) negative. The purpose of this study was to further examine the efficacy and safety of cyclin- dependent kinase 4/6 inhibitors (CDK4/6Is) in combination with endocrine therapy as a recovery treatment for advanced breast cancer patients.
Methods: The risk of bias for each included study was assessed using the Cochrane Risk of Bias Tool. The Cochrane Q value, combined with the I2 statistics, were selected to be tested for heterogeneity across the studies. The generic inverse variance was used to pool the hazard ratio and 95% CI of progression-free survival (PFS) and overall survival (OS), while pooled RRs and 95% CI were conducted using the Mantel- Haenszel to appraise the overall response rate (ORR), clinical benefit rate (CBR), and any adverse effects.
Results: Eight random clinical trials were finally identified. The analysis showed that the duration of PFS was significantly longer in the CDK4/6Is group than in the control group (hazard ratio, 0.55; 95% CI, 0.51– 0.60; P},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/34463}
}